| Date | Title | Description |
| 01.07.2026 | Graph Therapeutics Raises $5 Million for Drug Discovery Programs | Graph Therapeutics, a company in the field of immunology and inflammation research, has closed a $5 million (approx. €4.4 million) funding round. The round was led by the Paris-based venture capital firm Daphni. With this investment, the co... |
| 23.06.2026 | Graph Therapeutics Raises $5 Million For Inflammation And Immunology Programs | Graph Therapeutics announced that it has raised $5 million in new funding, bringing its total funding to date to over $10 million, including non-dilutive funding. The new investment will support the advancement of the company’s therapeutics... |
| 19.06.2026 | Report Maps Five-point Plan For Scottish Deeptech Growth | Scotland has built a valuable pipeline of deep tech businesses and directs an unusually high share of venture capital into the sector, but researchers warn that too few companies are progressing into scaleups.
Scotland must rethink how it f... |
| 27.05.2026 | Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics | Bonito Biosciences, a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and”) Dalton
, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, a... |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 19.12.2025 | The rise and impact of AI in Biotechnology and Healthcare | - |
| 26.09.2025 | DaltonTx: £4 Million Seed Funding Raised For Drug Discovery Platform | United Kingdom-based DaltonTx has emerged from its development phase, announcing the completion of a £4 million seed financing round. This investment will fuel the company’s mission to develop advanced, AI-based discovery platforms. These p... |
| 22.07.2025 | Latent Labs aims to replace trial-and-error drug discovery with push-button design | Today Latent Labs launches Latent-X, a frontier AI model for push button protein design, which outperforms competing models under identical laboratory conditions.
Latent Labs is working to transform the expensive, labour-intensive, and high... |
| 13.02.2025 | Latent Labs: The New Frontier in Programmable Biology | In the world of biotechnology, a new player has emerged, ready to rewrite the rules. Latent Labs, a London-based startup, has burst onto the scene with a staggering $50 million in funding. This infusion of capital is not just a number; it’s... |
| 13.02.2025 | AI pioneer Dr Simon Kohl's Latent Labs emerges from stealth, raising $50M for programmable biology | AI foundation model builder Latent Labs today emerged from stealth with $50 million in total funding to accelerate their progress in programmable biology.
The company was founded by Dr Simon Kohl, previously a co-lead of DeepMind’s protein ... |
| 20.11.2024 | Winds of Change: Scotland's Offshore Energy Future Faces Challenges and Opportunities | Scotland stands at a crossroads. The winds of change are blowing, carrying both promise and peril. On one hand, a £2.5 million funding boost for offshore wind technology shines a light on innovation and sustainability. On the other, Dundee ... |
| 14.11.2024 | Dundee University Braces for Job Cuts Amid £30M Deficit | Dundee University has warned staff that job cuts are incoming as the institution faces a £30 million deficit in the coming financial year.
Principal and vice-chancellor, Iain Gillespie, sent an email to the university’s 3,000 staff, telling... |
| 20.09.2024 | Dundee Uni Wins for Innovation & Entrepreneurship at European Awards | The University of Dundee has been named Innovative & Entrepreneurial University of the Year at an awards ceremony celebrating entrepreneurship and engagement in higher education.
This year’s Triple E European Awards ceremony was held at... |
| 09.08.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE on Behalf of Shareholders | NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relat... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 24.06.2024 | EXAI DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action - EXAI | NEW YORK, June 24, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds those who purchased common stock or purchased call options or sold put options, including any common stock purchased or otherwise acquir... |
| 22.05.2024 | ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI | NEW YORK, May 22, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "... |
| 08.05.2024 | ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI | NEW YORK, May 8, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and... |
| 01.05.2024 | ROSEN, LEADING INVESTOR COUNSEL, Encourages Exscientia plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI | NEW YORK, May 1, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Exscientia plc (NASDAQ: EXAI) between March 23, 2022 and F... |
| 01.02.2024 | Salary data revealed: Here's how much 16 top US and European AI startups like OpenAI, Anthropic, and Hugging Face are paying staffers | Premium Tech Salary data revealed: Here's how much 16 top US and European AI startups like OpenAI, Anthropic, and Hugging Face are paying staffers
Riddhi Kanetkar, Tasmin Lockwood, and Callum Burroughs
2024-02-01T11:00:01Z
Share icon An cur... |
| 15.09.2023 | Первобытный страх перед нейросетями или круги на воде | Содержание статьи:
1. Вступление
2. Краткий обзор некоторых нейросетевых технологий, появившихся за последнее время и кардинально меняющих правила игры в отрасли
2.1 Pic2Recipe – пример применения нейросети в кулинарии
2.2 Microsoft 365 Cop... |
| 06.09.2023 | Air Street Capital's $121M Fund II backed by Spotify founder and Google DeepMind scientist | London-based VC Air Street Capital has announced its $121 million Fund II to back AI-first early-stage start-ups. In a statement from Nathan Benaich, founder and General Partner at Air Street Capital, he thanked angels from OpenAI, Google (... |
| 22.05.2023 | Exscientia Highlights “The Future of AI-enabled Drug Discovery” at SLAS Europe | Exscientia plc announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 202... |
| 15.05.2023 | Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage | Exscientia plc announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-... |
| 14.11.2022 | Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments | Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms
Exscientia plc and The University of Texas MD Anderson Cancer Center announced a strategic coll... |
| 31.08.2022 | Exscientia expands AI-powered drug discovery in Miami | Facebook
Tweet
Pin
LinkedIn
Email
By Riley Kaminer
In the future, all drugs will be discovered using artificial intelligence. And the future is now. That’s UK-based Exscientia’s claim. Now the firm has doubled down on its Miami footprint to... |
| 07.01.2022 | Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines | Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Collaborative efforts aim to accelerate drug discovery and improve clinical success
Agreement to utilize Exscie... |
| 27.12.2021 | DIGIT’s Biggest Scottish Deals of 2021 | Despite a difficult two years due to the pandemic and the impact of Brexit, Scottish companies have continued to see strong growth and gain access to extra funding.
Sectors such as banking, e-commerce, space and life sciences all saw substa... |
| 14.06.2021 | AI drug discovery startup latest to go public via $2.8B SPAC merger | AI drug discovery startup Valo announced it’s going public via a $2.8 billion SPAC merger with Khosla Ventures, expected to close in Q3 2021. Here’s what it does: Valo’s primary product Opal Computational Platform uses AI to identify new dr... |
| 10.05.2021 | DIGIT Deal Roundup Column | April 2021 | Funding and Investment Ten Bio
Dundee University tech spin-out Ten Bio gained more than £900,000 to aid the ‘transformation’ of pharmaceutical and cosmetic product testing.
The tech firm’s funding round was led by TRICAPITAL, with matched f... |
| 28.04.2021 | FRONTIER IP GROUP PLC
Frontier IP : Exscientia announces investment of up to $525m led by SoftBank | 28/4/2021
Exscientia announces investment of up to $525M
Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities
$225 million Series D round closed with access up to an additional $300 million at... |
| 28.04.2021 | SoftBank leads funding that could net up to $525M for Exscientia's AI drug platform | With two partnered drugs in the clinic, Exscientia is reeling in up to $525 million to push its own pipeline into clinical testing and continue developing an artificial intelligence-based technology toward autonomous drug design.
Oxford, U.... |
| 28.04.2021 | SoftBank leads funding that could net up to $525M for Exscientia's AI drug platform | With two partnered drugs in the clinic, Exscientia is reeling in up to $525 million to push its own pipeline into clinical testing and continue developing an artificial intelligence-based technology toward autonomous drug design.
SoftBank V... |
| 27.04.2021 | Exscientia Raises Up To $525M in Funding | Exscientia, an Oxford, England, UK-based clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, completed a $225m Series D funding round.
SoftBank Vision Fund 2 led the Series D and was joined by... |
| 04.03.2021 | Exscientia Closes $100M in Series C Financing | Exscientia, a Oxford, England, UK-based clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, raised 100m in Series C funding.
Funds managed by BlackRock joined the Series C round which already in... |
| 15.01.2021 | Exscientia Receives A $4.2 Million Grant From The Gates Foundation To Develop New Medicines And Treatments For Infectious Diseases | Pharmaceutical companies are leveraging the power of technologies such as artificial intelligence ... [+] and machine learning to discover new drugs, manufacturing processes, and clinical trialsgetty |
| 08.01.2021 | Alkermes promotes from within to find new CFO and COO in rebound effort; Moderna vet Robert Dolski joins Checkmate as CFO | Iain Brown
→ Vowing to find a groove after a string of bogeys on the scorecard, Richard Pops has shaken up the C-suite at Alkermes, staying in-house by tapping Blair Jackson as COO and Iain Brown as CFO. Jackson, who began his t... |
| 28.12.2020 | Oxford-based Exscientia uses AI to accelerate delivery of new treatments; gets €3.44M from Gates Foundation | Oxford-based leading pharmatech company Exscientia deploys Artificial Intelligence to drive drug discovery. It is claimed to be a pioneer in using AI to design a novel molecule to enter the clinic. Now, this company has raised funding to id... |
| 26.05.2020 | UK medtech company Exscientia raises $60 million to apply AI to drug discovery | British AI drug discovery company Exscientia has raised $60 million in a Series C financing round led by a new investor, Denmark’s Novo Holdings, with existing investors such as Evotec, Bristol Myers Squibb, and GT Healthcare Capital chippi... |
| 19.05.2020 | Rallybio scores $145M, unveils lead rare disease program | When a trio of Alexion veterans started Rallybio, they vowed to take an “agnostic” approach to new medicines, because “diseases have no boundaries, so why should we?” Two years later, they’ve raised $145 million to bankroll a pipeline of ea... |
| 02.04.2020 | UK tech companies tackling Covid-19 – from detection to vaccination | The 2020 Tech Nation Report revealed that UK healthtech investment has doubled since 2017, reaching £1.7bn in 2019. And this world-leading sector has just become more crucial than ever. Faced with a global pandemic, innovative scaling compa... |
| 02.03.2020 | Do androids dream of electric lawsuits? Current IP law ill-suited for AI in drug discovery, panelist says | “It’s almost like there’s something new going on here that current IP law is not well-suited to protect,” said panelist Richard Assmus, a partner at Mayer Brown’s Chicago office.
Use of AI/ML in drug discovery and development has fed the gr... |
| 04.02.2020 | На человеке впервые испытают лекарство, разработанное AI | Александра Кукуть 4 февраля 2020, 09:35 На человеке впервые испытают лекарство, разработанное AI
В марте начнутся первые в истории клинические исследования лекарственного средства, которое полностью спроектировано искусственным интеллектом,... |
| - | The 9 healthcare startups that took in the most cash as VCs made record bets on transforming pharmacies and biotech | Noom cofounder and CEO Saeju Jeong. Noom This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Global healthcare startups raised a record $34.7 billion in 2021's second quarter.
Caris Life Scie... |
| - | Do androids dream of electric lawsuits? Current IP law ill-suited for AI in drug discovery, panelist says | L-R: Richard Assmus, David Opderbeck, Lori Bennett, Brian Nolan
As more companies use artificial intelligence and machine learning in the process of drug discovery and development, that raises a big question: Who owns the intellectual prope... |
| - | AI drug discovery startup latest to go public via $2.8B SPAC merger | AI drug discovery startup Valo announced it’s going public via a $2.8 billion SPAC merger with Khosla Ventures, expected to close in Q3 2021. Here’s what it does: Valo’s primary product Opal Computational Platform uses AI to identify new dr... |
| - | 3 факта перед IPO Exscientia (EXAI) | Exscientia предоставляет платформу на основе искусственного интеллекта(AI) для открытия и разработки новых лекарств.
0 Обсудить
203 просмотров
Подобные Exscientia компании пытаются ускорить разработку новых лекарств с помощью внедрения испо... |
| - | Exscientia Secures $100M To Expand AI Drug Discovery Platform | What You Should Know:
– Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock.
– This new capital, which will be used... |
| - | Exscientia Completes $100 million Series C Financing Round With BlackRock Funds | OXFORD, England--(BUSINESS WIRE)--Mar 4, 2021--
Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C in... |
